Navigation Links
Yuma Therapeutics Awarded a Research Grant by the Alzheimer's Drug Discovery Foundation to Develop Novel Therapeutics for Alzheimer's Disease

NEW YORK, March 28, 2011 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded a grant of $249,810 to Yuma Therapeutics Corporation (Yuma) to develop small molecules to treat Alzheimer's disease.


The award will fund work to develop Yuma's innovative disease-modifying pharmaceutical compounds that target neurofibrillary tangles resulting from abnormal forms of the protein tau, which represents a promising new approach with potential to affect disease progression in Alzheimer's disease.

"We are excited to support Yuma Therapeutics innovative program in this area," said Howard Fillit, M.D., executive director of the ADDF.  "Small molecule therapeutics targeting the tau pathway could result in a disease-modifying therapy for Alzheimer's disease."

"We are honored to be selected for this peer-reviewed grant, which recognizes the promise of Yuma's approach to generating novel Alzheimer's disease therapies," said Yukari Y. Perrella, founder and president of Yuma.  "We look forward to interacting with the ADDF team."

About the Alzheimer's Drug Discovery Foundation (

The ADDF is the only public charity whose sole mission is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's disease, related dementias and cognitive aging. Since 1998, the ADDF has granted more than $45 million to fund over 325 Alzheimer's drug discovery and development programs in academic centers and biotechnology companies in 17 countries. 

About Yuma Therapeutics Corporation (

Yuma Therapeutics is a privately held biopharmaceutical company focused on developing novel disease-modifying small molecule drugs to treat neurodegenerative diseases.  The Company is developing pharmaceutical compounds that target the tau pathway, a promising new approach to affect the disease progression of Alzheimer's disease.

SOURCE Alzheimer's Drug Discovery Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mersana Therapeutics Initiates Phase 1b Extension Study of XMT-1001 in Gastric Cancer and Non-Small Cell Lung Cancer
2. Reportlinker Adds Therapeutics for Immune System Disorders
3. Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis
4. Echo Therapeutics Hires Two Seasoned Medical Device and Diagnostics Executives
5. Pervasis Therapeutics Announces Late-Breaking Oral Presentation at American Association for Cancer Research Annual Meeting
6. Echo Therapeutics Announces 2010 Financial Results
7. Nile Therapeutics Reports 2010 Fourth Quarter and Full Year Financial Results
8. Reportlinker Adds Methicillin-Resistant Staphylococcus Aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
9. Halozyme Therapeutics Reports Fourth Quarter and Year End 2010 Financial Results
10. Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results
11. PNP Therapeutics Meets Important Financial and Regulatory Objectives in Development of New Cancer Therapies
Post Your Comments:
(Date:11/30/2015)... KIRKLAND, Wash. , Nov. 30, 2015 /PRNewswire/ ... of Post-Processing services, is pleased to announce a ... of medical imaging services. Building on its ISO-9001:2008 ... adopted and implemented comprehensive Core Lab protocols and ... wide variety of research activities.  Their Core Lab ...
(Date:11/30/2015)... 30, 2015 Mexico Healthcare and Life Sciences ... Report 2015 . --> Pharmaboardroom releases its new 98-page ... Latin America , a country of over 122 million ... of over 122 million people. --> It offers companies, ... life sciences insights into the second largest pharma and healthcare market ...
(Date:11/30/2015)... , November 30, 2015 Elbit ... the "Company") announced today that it was informed by InSightec ... Drug Safety (MFDS) has approved its Exablate Neuro system ... --> --> Insightec,s Exablate Neuro ... alternative that combines two technologies: Focused Ultrasound, which is ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... , ... The Foundation for Breast and Prostate Health (FBPH)—a ... with the award-winning creator and writer of Downton Abbey Julian Fellowes to host ... Union League of Philadelphia. , The benefit, titled “An Evening with Julian ...
(Date:11/30/2015)... PA (PRWEB) , ... November 30, 2015 , ... ... Specialty Ingredients (ASI) as their exclusive channel partner for the Nutraceutical Specialties products ... markets in the US, effective immediately. , “We are pleased to announce ...
(Date:11/30/2015)... ... November 30, 2015 , ... California-based i2i Systems, a ... today that Michigan-based Family Health Center (FHC) has selected i2iTracks as their population ... was awarded the largest Affordable Care Act grant for Federally Qualified Health Centers ...
(Date:11/30/2015)... PITTSBURGH, PA (PRWEB) , ... November 30, 2015 , ... ... quality of life in the womb. "My last baby had high blood pressure due ... way for mothers to protect their babies from noise pollution as well as radio ...
(Date:11/30/2015)... ... November 30, 2015 , ... In an interview with Andy ... a top ophthalmologist on Long Island’s east end. During the broadcast, entitled “Eyes: the ... and treatment of glaucoma and cataracts, and how a visit with his grandmother to ...
Breaking Medicine News(10 mins):